84 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
37
Identification of High-Potency Human TLR8 and Dual TLR7/TLR8 Agonists in Pyrimidine-2,4-diamines.
University of Minnesota
14
Incorporation of Phosphonate into Benzonaphthyridine Toll-like Receptor 7 Agonists for Adsorption to Aluminum Hydroxide.
Genomics Institute of Novartis Research Foundation
24
Structure-Based Design of Human TLR8-Specific Agonists with Augmented Potency and Adjuvanticity.
University of Kansas
6
Structural requirements for TLR7-selective signaling by 9-(4-piperidinylalkyl)-8-oxoadenine derivatives.
Glaxosmithkline
19
Human Toll-like receptor 8-selective agonistic activities in 1-alkyl-1H-benzimidazol-2-amines.
University of Kansas
22
Dihydropyrrolo[2,3-d]pyrimidines: Selective Toll-Like Receptor 9 Antagonists from Scaffold Morphing Efforts.
Sumitomo Dainippon Pharma
1
Identification and optimization of pteridinone Toll-like receptor 7 (TLR7) agonists for the oral treatment of viral hepatitis.
Gilead Sciences
3
Exquisite selectivity for human toll-like receptor 8 in substituted furo[2,3-c]quinolines.
University of Kansas
6
Discovery of Imidazoquinolines with Toll-Like Receptor 7/8 Independent Cytokine Induction.
TBA
16
Structure-activity relationships in human Toll-like receptor 8-active 2,3-diamino-furo[2,3-c]pyridines.
University of Kansas
16
Toll-like receptor (TLR)-7 and -8 modulatory activities of dimeric imidazoquinolines.
University of Kansas
16
Synthesis and biological evaluation of 8-oxoadenine derivatives as toll-like receptor 7 agonists introducing the antedrug concept.
Dainippon Sumitomo Pharma
17
Discovery of Novel Isoxazole-Based Small-Molecule Toll-Like Receptor 8 Antagonists.
University of Bonn
24
Structure-Based Design of Novel TLR7/8 Agonist Payloads Enabling an Immunomodulatory Conjugate Approach.
Bristol Myers Squibb
9
Modulation of the Adjuvant Potential of Imidazoquinoline-Based TLR7/8 Agonists via Alum Adsorption.
Panjab University
1
Antibody-drug conjugates for targeted cancer therapy: Recent advances in potential payloads.
Shaoxing University
23
Heterocyclic-Modified Imidazoquinoline Derivatives: Selective TLR7 Agonist Regulates Tumor Microenvironment against Melanoma.
Southern Medical University
21
Design, Synthesis, and Biological Evaluation of New 2,6,7-Substituted Purine Derivatives as Toll-like Receptor 7 Agonists for Intranasal Vaccine Adjuvants.
Gwangju Institute of Science and Technology
17
Structure-Activity Relationships toward the Identification of a High-Potency Selective Human Toll-like Receptor-7 Agonist.
Panjab University
27
Discovery of the TLR7/8 Antagonist MHV370 for Treatment of Systemic Autoimmune Diseases.
Novartis Institutes for Biomedical Research
27
Identification and Optimization of Small Molecule Pyrazolopyrimidine TLR7 Agonists for Applications in Immuno-oncology.
Bristol Myers Squibb
33
Discovery of Novel TLR7 Agonists as Systemic Agent for Combination With aPD1 for Use in Immuno-oncology.
Bristol Myers Squibb
43
Small-Molecule Modulators Targeting Toll-like Receptors for Potential Anticancer Therapeutics.
West China Hospital
34
Generation and structure-activity relationships of novel imidazo-thienopyridine based TLR7 agonists: application as payloads for immunostimulatory antibody drug-conjugates.
Zymeworks
21
Recent advances in small molecule based cancer immunotherapy.
Southern Medical University
6
Novel Thienopyrrole Compounds for Treating Autoimmune Diseases and Inflammatory Conditions.
Smith, Gambrell & Russell
195
Structural evolution of toll-like receptor 7/8 agonists from imidazoquinolines to imidazoles.
Panjab University
50
If small molecules immunotherapy comes, can the prime be far behind?
Zhejiang University
10
Agonist and antagonist ligands of toll-like receptors 7 and 8: Ingenious tools for therapeutic purposes.
University of Montpellier
15
Structural Evolution and Translational Potential for Agonists and Antagonists of Endosomal Toll-like Receptors.
Csir-Indian Institute of Chemical Biology
9
Toll-like receptor 7 and 8 imidazoquinoline-based agonist/antagonist pairs.
University of Minnesota
34
Identification of 2-Pyridinylindole-Based Dual Antagonists of Toll-like Receptors 7 and 8 (TLR7/8).
Biocon Bristol Myers Squibb Research Center (Bbrc)
41
Development, Optimization, and In Vivo Validation of New Imidazopyridine Chemotypes as Dual TLR7/TLR9 Antagonists through Activity-Directed Sequential Incorporation of Relevant Structural Subunits.
Csir-Indian Institute of Chemical Biology
25
Small molecule approaches to treat autoimmune and inflammatory diseases (Part II): Nucleic acid sensing antagonists and inhibitors.
Roche Innovation Center Shanghai
14
Structure-Based Optimization of a Fragment-like TLR8 Binding Screening Hit to an
Novartis Institutes For Biomedical Research
30
Systematic Optimization of Potent and Orally Bioavailable Purine Scaffold as a Dual Inhibitor of Toll-Like Receptors 7 and 9.
Csir-Indian Institute of Chemical Biology
66
Structure-Based Design of Highly Potent Toll-like Receptor 7/8 Dual Agonists for Cancer Immunotherapy.
Beijing Advanced Innovation Center For Human Brain Protection
6
Novel Triazatricycle Compounds for Treating Autoimmune Diseases.
Smith, Gambrell & Russell
9
Further hit optimization of 6-(trifluoromethyl)pyrimidin-2-amine based TLR8 modulators: Synthesis, biological evaluation and structure-activity relationships.
University of Ljubljana
6
Novel Carbazoles for Treating Inflammatory and Autoimmune Diseases.
Smith, Gambrell & Russell
40
Identification of a Human Toll-Like Receptor (TLR) 8-Specific Agonist and a Functional Pan-TLR Inhibitor in 2-Aminoimidazoles.
University of Kansas
15
Discovery of potent, orally bioavailable in vivo efficacious antagonists of the TLR7/8 pathway.
Genomics Institute of The Novartis Research Foundation
32
Discovery of GS-9688 (Selgantolimod) as a Potent and Selective Oral Toll-Like Receptor 8 Agonist for the Treatment of Chronic Hepatitis B.
Gilead Sciences
11
Modulation of the Innate Immune Response by Targeting Toll-like Receptors: A Perspective on Their Agonists and Antagonists.
University of Siena
14
Optimization of 8-oxoadenines with toll-like-receptor 7 and 8 activity.
University of Montana
35
Discovery of Potent and Orally Bioavailable Small Molecule Antagonists of Toll-like Receptors 7/8/9 (TLR7/8/9).
Princ
28
Target-Based Identification and Optimization of 5-Indazol-5-yl Pyridones as Toll-like Receptor 7 and 8 Antagonists Using a Biochemical TLR8 Antagonist Competition Assay.
Genomics Institute of The Novartis Research Foundation
13
Further exploration of the structure-activity relationship of imidazoquinolines; identification of potent C7-substituted imidazoquinolines.
University of Kansas
15
Human Toll-like Receptor (TLR) 8-Specific Agonistic Activity in Substituted Pyrimidine-2,4-diamines.
University of Minnesota
30
Rationally Designed Small-Molecule Inhibitors Targeting an Unconventional Pocket on the TLR8 Protein-Protein Interface.
The University of Tokyo
32
Discovery of Novel Small Molecule Dual Inhibitors Targeting Toll-Like Receptors
University of Colorado Boulder
3
Identification and characterization of a novel chemotype for human TLR8 inhibitors.
Freie Universit£T Berlin
14
Structure-activity relationship analysis of imidazoquinolines with Toll-like receptors 7 and 8 selectivity and enhanced cytokine induction.
University of Minnesota
22
Design and Synthesis of N1-Modified Imidazoquinoline Agonists for Selective Activation of Toll-like Receptors 7 and 8.
University of Minnesota
3
Discovery of Small Molecules as Multi-Toll-like Receptor Agonists with Proinflammatory and Anticancer Activities.
University of Colorado Boulder
1
Crystalline form of capsid protein assembly inhibitor containing N hetero five-membered ring, and application thereof
Chia Tai Tianqing Pharmaceutical Group
69
HETEROCYCLIC G-PROTEIN-COUPLED RECEPTOR 52 (GPR52) AGONISTS
University Of Texas
381
3-(1H-IMIDAZOL-2-YL)-2,3,8,8A-TETRAHYDROINDOLIZIN-5(1H)-ONE DERIVATIVES USEFUL AS FACTOR XIA INHIBITORS
Janssen Pharmaceutica
7
NOVEL TRICYCLIC AROMATIC HETEROCYCLIC COMPOUND AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND USE THEREOF
Shanghai Longwood Biopharmaceuticals
78
Compounds for the treatment of BRAF-associated diseases and disorders
Array Biopharma
97
Formulations of Tie-2 activators and methods of use thereof
Eyepoint Pharmaceuticals
17
Compounds as neuronal histamine receptor-3 antagonists and uses thereof
Xw Laboratories
47
Substituted pyrazolo/imidazolo bicyclic compounds as PDE2 inhibitors
Merck Sharp & Dohme
14
Chemokine CXCR1 and CXCR2 receptor antagonist compounds, and use thereof in the treatment of chemokine-mediated pathologies
Galderma Research & Development
19
Substituted pyrrolidines as factor xia inhibitors for the treatment thromboembolic diseases
Ono Pharmaceutical
8
Tricyclic heterocycles useful as dipeptidyl peptidase-IV inhibitors
Merck Sharp & Dohme